DarioHealth (DRIO) Projected to Announce Quarterly Earnings on Thursday

DarioHealth (NASDAQ:DRIO) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect DarioHealth to announce earnings of ($0.51) per share and revenue of $5.21 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

DarioHealth (NASDAQ:DRIO) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.37. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.92 million. On average, analysts expect DarioHealth to post ($2.94) EPS for the current fiscal year and ($2.17) EPS for the next fiscal year.

DarioHealth Stock Performance

DRIO opened at $2.39 on Wednesday. The stock’s 50 day moving average price is $5.36 and its 200-day moving average price is $7.47. DarioHealth has a one year low of $1.70 and a one year high of $14.77. The company has a quick ratio of 1.92, a current ratio of 2.31 and a debt-to-equity ratio of 0.56.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. BTIG Research began coverage on DarioHealth in a research note on Tuesday, October 27th. They set a “buy” rating and a $6.00 price target for the company. TD Cowen dropped their price objective on DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DarioHealth in a research report on Tuesday, October 6th. Finally, Alliance Global Partners assumed coverage on DarioHealth in a research report on Wednesday, August 19th. They issued a “buy” rating and a $12.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

DarioHealth Company Profile

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health. The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.